CA2817846A1 - Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer - Google Patents

Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer Download PDF

Info

Publication number
CA2817846A1
CA2817846A1 CA2817846A CA2817846A CA2817846A1 CA 2817846 A1 CA2817846 A1 CA 2817846A1 CA 2817846 A CA2817846 A CA 2817846A CA 2817846 A CA2817846 A CA 2817846A CA 2817846 A1 CA2817846 A1 CA 2817846A1
Authority
CA
Canada
Prior art keywords
receptor antagonist
prolactin receptor
prolactin
patient
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2817846A
Other languages
English (en)
French (fr)
Inventor
Wen Y. Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolix Inc
Original Assignee
Oncolix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolix Inc filed Critical Oncolix Inc
Publication of CA2817846A1 publication Critical patent/CA2817846A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA2817846A 2010-11-17 2011-11-16 Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer Abandoned CA2817846A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/948,329 US8648046B2 (en) 2009-02-26 2010-11-17 Compositions and methods for visualizing and eliminating cancer stem cells
US12/948,329 2010-11-17
PCT/US2011/061040 WO2012068282A1 (en) 2010-11-17 2011-11-16 Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer

Publications (1)

Publication Number Publication Date
CA2817846A1 true CA2817846A1 (en) 2012-05-24

Family

ID=45349276

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2817846A Abandoned CA2817846A1 (en) 2010-11-17 2011-11-16 Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer

Country Status (9)

Country Link
US (2) US8648046B2 (https=)
EP (1) EP2640412B1 (https=)
JP (3) JP6306886B2 (https=)
KR (1) KR20140009196A (https=)
CN (2) CN103298481A (https=)
AU (1) AU2011328935B2 (https=)
CA (1) CA2817846A1 (https=)
IL (1) IL226271A (https=)
WO (1) WO2012068282A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167750A2 (en) * 2012-05-11 2013-11-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
CN105102480B (zh) 2012-12-24 2019-04-16 艾伯维公司 催乳素受体结合蛋白及其用途
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
EP3707166A4 (en) * 2017-11-06 2021-11-24 Daniel J. Monticello CHEMICAL ANTIGENIC RECEPTOR SYSTEMS WITH NEGATIVE DOMINANT LIGAND
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN113956356B (zh) * 2021-10-27 2023-05-02 福州迈新生物技术开发有限公司 抗prl蛋白单克隆抗体、细胞系及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1055932A (en) 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
DE2616086C2 (de) 1976-04-13 1986-04-03 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Substanz zur Verwendung in einem kolloidalen Blutvolumenersatzmittel aus Hydroxyethylstärke und Hämoglobin
EP1079851B1 (en) * 1998-05-12 2007-07-04 Greenville Hospital System Use of anti-prolactin agents to treat cancer
EP2180054A1 (en) * 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1282642B1 (en) * 2000-05-09 2006-09-06 Greenville Hospital System Therapeutic pore-forming peptides
US7001888B2 (en) * 2002-03-29 2006-02-21 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
BR0314106A (pt) 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Polipeptìdeos hasilados, especialmente eritropoietina hasilada
NZ541122A (en) * 2002-12-26 2008-09-26 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US8754031B2 (en) * 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
US20050238628A1 (en) * 2004-04-08 2005-10-27 Blau Carl A Methods for treating cancer
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
CN100479863C (zh) * 2006-09-06 2009-04-22 中国医学科学院北京协和医院 Cofilin 1与癌症的紫杉烷类化疗药物耐药性的相关性
EP2094291A1 (en) * 2006-12-21 2009-09-02 Novo Nordisk A/S Dimeric prolactin receptor ligands
WO2009089537A2 (en) * 2008-01-11 2009-07-16 Northwestern University Anti-cancer compounds
US8754035B2 (en) * 2009-02-26 2014-06-17 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells

Also Published As

Publication number Publication date
JP2016029110A (ja) 2016-03-03
CN106177915A (zh) 2016-12-07
IL226271A (en) 2017-05-29
KR20140009196A (ko) 2014-01-22
JP2013544254A (ja) 2013-12-12
US8648046B2 (en) 2014-02-11
WO2012068282A1 (en) 2012-05-24
JP6306886B2 (ja) 2018-04-04
EP2640412B1 (en) 2017-08-02
IL226271A0 (en) 2013-07-31
AU2011328935B2 (en) 2016-08-11
EP2640412A1 (en) 2013-09-25
JP2018062527A (ja) 2018-04-19
AU2011328935A1 (en) 2013-05-30
US20130231286A1 (en) 2013-09-05
CN103298481A (zh) 2013-09-11
US20110065639A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
EP2640412B1 (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
CA2753804C (en) Compositions and methods for visualizing and eliminating cancer stem cells
US8754031B2 (en) Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
HK1231759A1 (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
HK1189171A (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
HK1231758A1 (en) Compositions and methods for visualizing and eliminating cancer stem cells
HK1166693A (en) Compositions and methods for visualizing and eliminating cancer stem cells
EP3984547A1 (en) Peptides for the treatment of cancer
JP7254020B2 (ja) 融合遺伝子を含有するがんを治療する方法
AU2024252321A1 (en) Administration of a beta-catenin antagonist and methods of use
KR20240133687A (ko) 1차 요법으로 axl 유인 수용체를 이용한 국소 진행성 또는 전이성 췌장 선암종의 치료 방법
KR20200068272A (ko) PNA-pHLIP 접합체를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
Lim et al. Biomarkers in GIST

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161115

FZDE Discontinued

Effective date: 20210222